69 ECG changes in Fabry disease Table 1: Participants’ characteristics Number of patients, n (%) All 133 (100%) Men 48 (36%) Women 85 (64%) General Number of ECGs 1,995 819 1,176 Number of ECGs per patient, median (range) 15 (4-66) 18 (4-66) 15 (4-47) Age at first ECG (years), median (range) 38 (18-68) 27 (18-58) 41 (18-68) Age at last ECG (years), median (range) 48 (19-82) 37 (19-65) 50 (20-82) Follow-up duration (years), median (range) 9 (0-18) 8 (0-18) 9 (0-17) Enzyme replacement therapy (ERT) Patients on ERT, n (%) 106 (80%) 45 (94%) 61 (72%) Duration of ERT treatment (years), median (range) 7 (0-17) 9 (0-17) 7 (0-14) Cardiovascular comorbidities Smoking†, n (%) 47 (35%) 16 (33%) 31 (37%) Hypertension†, n (%) 22 (17%) 7 (15%) 15 (18%) Obesity†, n (%) 15 (11%) 0 (0%) 15 (18%) Diabetes mellitus†, n (%) 2 (1.5%) 0 (0%) 2 (2%) Dyslipidemia†, n (%) 6 (5%) 0 (0%) 6 (7%) Laboratory findings at last ECG eGFR- CKD EPI formula (ml/min), median (range) 87 (15-144) 101 (15-144) 85 (22-131) Urine albumin (mg/ 24 hours), median (range) 42 (3-3498) 54 (4-3498) 42 (3-1175) Presence of microalbuminuria**, n (%) 65/115 (57%) 25/40 (63%) 40/75 (53%) Cardiac MRI findings at last ECG Left ventricular mass index (g/m2), median (range) 63 (32-141) 78 (43-141) 60 (32-117) Presence of late Gadolinium enhancement, n (%) 60/118 (51%) 17/40 (43%) 43/78 (55%) Cardiovascular events during follow-up Major adverse Cardiovascular events, n (%) 22 (17%) 11 (23%) 11 (13%) Age at MACE (years), median (range) 55 (33-70) 55 (33-66) 66 (34-70) Number of controls, n (%) All 3893 (100%) Men 1667 (43%) Women 2226 (57%) General Age at ECG, median (range) 46 (18-71) 45 (18-65) 46 (18-71) Cardiovascular comorbidities Smoking*, n (%) 2377 (61%) 1049 (63%) 1328 (60%) Hypertension*, n (%) 983 (25%) 514 (31%) 469 (21%) 3
RkJQdWJsaXNoZXIy MTk4NDMw